Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly

Next Previous
Trial Profile

Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 09 Dec 2020 According to a Sinovac Biotech media release, results from this study was published in the Human Vaccines and Immunotherapeutics medical journal.
  • 09 Dec 2020 According to a Sinovac Biotech media release, the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Companys 23-Valent Pneumococcal Polysaccharide (PPV) Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above.
  • 12 Oct 2017 According to a Sinovac Biotech media release, the company has filed the NDA for its 23-valent Pneumococcal Polysaccharide Vaccine to the CFDA on 3 August 2017. This vaccine is used to prevent streptococcus pneumoniae (pneumococcus) infections such as pneumonia and septicemia among adults aged 65 or older, adults with serious long-term health problems, smokers, and children older than two years with serious long-term health problems.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top